Journal of Traditional Chinese Medicine ›› 2023, Vol. 43 ›› Issue (2): 231-238.DOI: 10.19852/j.cnki.jtcm.2023.02.004
• Meta Analysis • Previous Articles Next Articles
DAI Linfeng1,2, ZHUANG Yan1,2, Lü Hai1,2, CHEN Mingqi1,2(), WANG Xing1,2()
Received:
2022-01-16
Accepted:
2022-04-01
Online:
2023-04-15
Published:
2023-03-14
Contact:
Prof. WANG Xing, Department of Critical Care Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, China. wangxing1964@163.com. Dr. CHEN Mingqi, Affiliated Hospital of Nanjing University of Chinese Medicine, Department of Critical Care Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, China. chengxin5320@126.com.Telephone: +86-13913983636; +86-15850505338
Supported by:
DAI Linfeng, ZHUANG Yan, Lü Hai, CHEN Mingqi, WANG Xing. Effectiveness and safety of Suhuang Zhike capsule (苏黄止咳胶囊) as adjuvant treatment for acute exacerbation of chronic obstructive pulmonary disease: a systematic review and Meta-analysis[J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 231-238.
Study | N (T/C) | Age (T/C) (mean±SD) | Course of Treatment (days) | Interventions | Outcome | |
---|---|---|---|---|---|---|
T | C | |||||
Yang HJ et al 2014 | 30/30 | 61.8±9.2/64.5±8.4 | 10 | SHZK+C | CT | ①② |
Wang XP et al 2016 | 30/30 | 65.9±6.2/60.3±4.6 | 10 | SHZK+C | AH+ICS+CT | ①⑤ |
Huang YF et al 2017 | 45/45 | 67.57±5.25/68.05±5.57 | 56 | SHZK+C | LABA+ICS+CT | ②④⑥ |
Zhou YL et al 2017 | 60/60 | 68.4±5.6/68.8±6.2 | 7 | SHZK+C | AH+CT | ①②③⑤ |
Zhao NK, Li Y 2017 | 53/54 | 67.57±5.25/68.05±5.57 | 28 | SHZK+C | CT | ②④⑥ |
Li J, Wang D 2018 | 38/38 | 60.8±4.4/61.2±4.5 | 14 | SHZK+C | AH+ICS+CT | ①⑤ |
Ou CL et al 2018 | 60/60 | 65.42±4.68/65.05±4.68 | 60 | SHZK+C | CT | ②⑥ |
Zhang YL et al 2018 | 42/42 | 64.26±7.42/64.18±7.35 | 14 | SHZK+C | LABA+ICS | ①②③ |
Wu MJ 2018 | 30/30 | 67.3±5.68/60.1±6.14 | 14 | SHZK+C | SAMA+AH+CT | ①④⑤ |
Wang YM et al 2019 | 80/80 | 61.8±5.5/60.9±5.9 | 10 | SHZK+C | AH+CT | ①②⑤ |
Ren JQ 2019 | 44/44 | 75.5±4.3/75.3±4.2 | 7 | SHZK+C | SAMA+AH+SABA+ICS+CT | ①②③⑤ |
Peng GY 2019 | 36/36 | 65.41±5.79/64.29±5.76 | 30 | SHZK+C | LABA+ICS+CT | ②⑥ |
Chang WY 2020 | 49/49 | 65.6±4.7/64.3±4.5 | 56 | SHZK+C | SAMA+ICS+AH+CT | ①⑤ |
Table 1 General characteristics of included studies
Study | N (T/C) | Age (T/C) (mean±SD) | Course of Treatment (days) | Interventions | Outcome | |
---|---|---|---|---|---|---|
T | C | |||||
Yang HJ et al 2014 | 30/30 | 61.8±9.2/64.5±8.4 | 10 | SHZK+C | CT | ①② |
Wang XP et al 2016 | 30/30 | 65.9±6.2/60.3±4.6 | 10 | SHZK+C | AH+ICS+CT | ①⑤ |
Huang YF et al 2017 | 45/45 | 67.57±5.25/68.05±5.57 | 56 | SHZK+C | LABA+ICS+CT | ②④⑥ |
Zhou YL et al 2017 | 60/60 | 68.4±5.6/68.8±6.2 | 7 | SHZK+C | AH+CT | ①②③⑤ |
Zhao NK, Li Y 2017 | 53/54 | 67.57±5.25/68.05±5.57 | 28 | SHZK+C | CT | ②④⑥ |
Li J, Wang D 2018 | 38/38 | 60.8±4.4/61.2±4.5 | 14 | SHZK+C | AH+ICS+CT | ①⑤ |
Ou CL et al 2018 | 60/60 | 65.42±4.68/65.05±4.68 | 60 | SHZK+C | CT | ②⑥ |
Zhang YL et al 2018 | 42/42 | 64.26±7.42/64.18±7.35 | 14 | SHZK+C | LABA+ICS | ①②③ |
Wu MJ 2018 | 30/30 | 67.3±5.68/60.1±6.14 | 14 | SHZK+C | SAMA+AH+CT | ①④⑤ |
Wang YM et al 2019 | 80/80 | 61.8±5.5/60.9±5.9 | 10 | SHZK+C | AH+CT | ①②⑤ |
Ren JQ 2019 | 44/44 | 75.5±4.3/75.3±4.2 | 7 | SHZK+C | SAMA+AH+SABA+ICS+CT | ①②③⑤ |
Peng GY 2019 | 36/36 | 65.41±5.79/64.29±5.76 | 30 | SHZK+C | LABA+ICS+CT | ②⑥ |
Chang WY 2020 | 49/49 | 65.6±4.7/64.3±4.5 | 56 | SHZK+C | SAMA+ICS+AH+CT | ①⑤ |
Figure 3 Meta-analysis of ORR and lung function in included studies A: forest plot of ORR; B: forest plot of FEV1; C: forest plot of FVC; D: forest plot of FEV1/FVC; E: forest plot of PEF. ORR: objective response rate; forced vital capacity; FEV1: forced expiratory volume in the first second; FVC: forced vital capacity; PEF: peak expiratory flow.
Figure 4 Meta-analysis of blood gas analysis and blood routine examination in included studies A: forest plot of PaO2; B: forest plot of PaCO2; C: forest plot of WBC; D: forest plot of NE; E: forest plot of CRP. PaO2: partial pressure of oxygen; PaCO2: partial pressure of carbon dioxide; WBC: white blood cell; NE: neutrophilic granulocyte; CRP: c-reactive type.
1. | Chen YT, Miao K, Zhou L, Xiong WN. Stem cell therapy for chronic obstructive pulmonary disease. Chin Med J (Engl) 2021; 134: 1535-45. |
2. |
Hurst JR, Siddiqui MK, Singh B, Varghese P, Holmgren U, de Nigris E. A systematic literature review of the humanistic burden of COPD. Int J Chron Obstruct Pulmon Dis 2021; 16: 1303-14.
DOI URL |
3. |
Barreiro E, Wang X, Tang J. COPD: preclinical models and emerging therapeutic targets. Expert Opin Ther Targets 2019; 23: 829-38.
DOI URL |
4. |
Wang Y, Xu J, Meng Y, Adcock IM, Yao X. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis 2018; 13: 3341-8.
DOI URL |
5. |
Afroz N, Gutzwiller FS, Mackay AJ, Naujoks C, Patalano F, Kostikas K. Patient-Reported Outcomes (PROs) in COPD clinical trials: trends and gaps. Int J Chron Obstruct Pulmon Dis 2020; 15: 1789-1800.
DOI URL |
6. |
Ko FW, Chan KP, Hui DS, et al. Acute exacerbation of COPD. Respirology 2016; 21: 1152-65.
DOI PMID |
7. |
Hogea SP, Tudorache E, Fildan AP, Fira-Mladinescu O, Marc M, Oancea C. Risk factors of chronic obstructive pulmonary disease exacerbations. Clin Respir J 2020; 14: 183-97.
DOI URL |
8. |
Whittaker BS, Braman S. Recent advances in the management of acute exacerbations of chronic obstructive pulmonary disease. Med Clin North Am 2020; 104: 615-30.
DOI URL |
9. | Duan X, Wu J, Huang X, et al. Comparative efficacy of Chinese herbal injections for treating acute exacerbation of chronic obstructive pulmonary disease: a bayesian network Meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2018; 2018: 7942936. |
10. |
Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med 2020; 41: 421-38.
DOI PMID |
11. | Fan Y, Wen X, Zhang Q, et al. Effect of Traditional Chinese Medicine Bufei granule on stable chronic obstructive pulmonary disease: a systematic review and Meta-analysis based on existing evidence. Evid Based Complement Alternat Med 2020; 2020: 3439457. |
12. | Yang J. Observation of the effects of the Suhuang Zhike capsule on acute bronchitis. J Biol Regul Homeost Agents 2017; 31: 453-57. |
13. | Zhu ML, Zhang FY, Zhang H, et al. Critical quality attribute assessment of big brand Traditional Chinese Medicine: process quality control method of Suhuang Zhike capsules intermediate based on physical properties of powder and granules. Zhong Guo Zhong Yao Za Zhi 2021; 46: 1636-43. |
14. | Wang ZH, Zhang MP, Zhang HX, et al. Pharmacoeconomic evaluation of Suhuang Zhike capsules using Markov model for inpatients with acute exacerbation of chronic obstructive pulmonary disease. Zhong Guo Zhong Yao Za Zhi 2021; 46: 2588-93. |
15. | Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease:the GOLD science committee report 2019. Eur Respir J 2019; 53-4. |
16. | Yang H, Qiu D, Du F. Eliminating phlegm effect of Suhuang Zhike Jiaonang on acute exacerbation of chronic obstructive pulmonary disease. Ji Ceng Yi Xue Lun Tan 2014; 18: 2891-2. |
17. | Wang X, Wang X, Wan Y, et al. Clinical evaluation of supportive treatment with Suhuangzhike capsules against acute exacerbation of chronic obstructive pulmonary disease. Zhong Guo Yi Yuan Yao Xue Za Zhi 2016; 36: 937-9. |
18. | Huang Y, Sun G, Zhou L, Lu C, Chang S. Observation and analysis of clinical efficacy of Suhuang Zhike capsule for patients with acute exacerbation of chronic obstructive pulmonary disease. Shi Jie Zhong Yi Yao 2017; 12: 2023-7. |
19. | Zhou Y, Xu H, Zhou H. Clinical observation of Suhuang Zhike capsule in adjuvant treatment of senile chronic obstructive pulmonary disease in acute exacerbation stage. Zhong Yi Yao Dao Bao 2017; 23: 89-91. |
20. | Zhao N, Li Y. Long term follow up study of Suhuang Zhike capsule treatment of patients with chronic obstructive pulmonary disease. Liaoning: Liaoning Zhong Yi Za Zhi 2017; 44: 1235-8. |
21. | Li J, Wang D. Clinical observation of Suhuang Zhike capsule in treating acute exacerbation of chronic obstructive pulmonary disease. Yao Wu Ping Jia 2018; 15: 57-8. |
22. | Ou C, Zhang W, Li D. Clinical eficacy of the Suhuang Zhike capsule on acute exacerbation of chronic obstructive pulmonary. Zhong Guo Lin Chuang Yan Jiu 2018; 10: 14-6. |
23. | Zhang Y, Yao B, Wu Y, Xu Z. Effect of Suhuang Zhike capsule combined with fluticasone propionate and salmeterol in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Lin Chuang Yi Xue Yan Jiu Yu Shi Jian 2018; 3: 20-1. |
24. | Wu M. Observation on curative effect of Suhuang Zhike capsule in the acute exacerbation of chronic obstructive pulmonary disease. Hai Xia Yao Xue 2018; 30: 129-31. |
25. | Wang Y, Ji M, Song S, Hua R. Clinical study on Suhuang Zhike capsules combined with ambroxol in treatment of acute exacerbation of chronic obstructive pulmonary disease. Xian Dai Yao Wu Yu Lin Chuang 2019; 34: 2381-5. |
26. | Ren J. Effect of Suhuang Zhike capsule on pulmonary function, blood gas analysis, serum PCT and CRP in patients with acute exacerbation of chronic obstructive pulmonary disease. Xian Dai Zhong Xi Yi Jie He Za Zhi 2019; 28: 1442-5. |
27. | Peng G. Clinical effect of Suhuang Zhike capsule in treating patients with acute exacerbation of chronic obstructive pulmonary disease. Zhong Guo Chu Fang Yao 2019; 17: 140-1. |
28. | Chang W. Analysis of the curative effect of Suhuang Zhike capsule in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Heilongjiang: Heilongjiang Zhong Yi Yao 2020; 49: 78-9. |
29. | Kenn K, Gloeckl R, Leitl D, et al. Protocol for an observational study to identify potential predictors of an acute exacerbation in patients with chronic obstructive pulmonary disease (the PACE Study). BMJ Open 2021; 11: e43014. |
30. | Cai BQ, Cai SX, Chen RC, et al. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People's Republic of China. Int J Chron Obstruct Pulmon Dis 2014; 9: 381-95. |
31. | Cong S, Yao JY, Fan J, et al. Analysis on awareness of chronic obstructive pulmonary disease (COPD) status and related knowledge in patients with COPD in China, 2014-2015. Zhong Hua Liu Xing Bing Xue Za Zhi 2020; 41: 1034-40. |
32. |
Mantero M, Rogliani P, Di Pasquale M, et al. Acute exacerbations of COPD: risk factors for failure and relapse. Int J Chron Obstruct Pulmon Dis 2017; 12: 2687-93.
DOI URL |
33. |
Zhou A, Zhou Z, Zhao Y, Chen P. The recent advances of phenotypes in acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2017; 12: 1009-18.
DOI URL |
34. | Gu C, Peng W, Wang Z, Xu Y, Han D, Zhou X. Suhuang Zhike capsules for the treatment of cough variant asthma: a Meta-analysis. Evid Based Complement Alternat Med 2020; 2020: 9485746. |
35. |
Agarwala P, Salzman SH. Six-minute walk test: clinical role, technique, coding, and reimbursement. Chest 2020; 157: 603-11.
DOI PMID |
36. |
Fermont JM, Masconi KL, Jensen MT, et al. Biomarkers and clinical outcomes in COPD: a systematic review and Meta-analysis. Thorax 2019; 74: 439-46.
DOI PMID |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
Sponsored by China Association of Chinese Medicine
& China Academy of Chinese Medical Sciences
16 Nanxiaojie, Dongzhimen Nei, Beijing, China. 100700 Email: jtcmen@126.com
Copyright 2020 Journal of Traditional Chinese Medicine. All rights reserved.